These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22199044)

  • 21. Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections.
    Canto de Cetina TE; Luna MO; Cetina Canto JA; Bassol S
    Contraception; 2004 Feb; 69(2):115-9. PubMed ID: 14759615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trial of a long-acting injectable contraceptive: NET-EN.
    Chaudhuri C; Mukherjea M
    Contracept Deliv Syst; 1984 Jan; 5(1):47-52. PubMed ID: 12312744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acceptability of the once-a-month injectable contraceptives Cyclofem and Mesigyna in Egypt.
    Hassan EO; el-Nahal N; el-Hussein M
    Contraception; 1994 May; 49(5):469-88. PubMed ID: 8045133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and sid effects.
    Sang GW; Shao QX; Ge RS; Ge JL; Chen JK; Song S; Fang KJ; He ML; Luo SY; Chen SF
    Contraception; 1995 Mar; 51(3):167-83. PubMed ID: 7621685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depot medroxyprogesterone injectable contraception at the University of Uyo Teaching Hospital, Uyo.
    Abasiattai AM; Udoma EJ; Ukeme E
    Ann Afr Med; 2010; 9(2):81-5. PubMed ID: 20587929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaginal wetness: an underestimated problem experienced by progestogen injectable contraceptive users in South Africa.
    Smit J; McFadyen L; Zuma K; Preston-Whyte E
    Soc Sci Med; 2002 Nov; 55(9):1511-22. PubMed ID: 12297238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
    Kaunitz AM
    Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experience with the use of depo-medroxyprogesterone acetate in a Nigerian population.
    Falase EA; Otolorin EO; Ladipo OA
    Afr J Med Med Sci; 1988 Dec; 17(4):209-13. PubMed ID: 2854367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: noresthisterone oenanthate and medroxyprogesterone acetate. 2. Bleeding patterns and side effects.
    Contraception; 1978 May; 17(5):395-406. PubMed ID: 657807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report.
    Contraception; 1983 Jul; 28(1):1-20. PubMed ID: 6226488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Injectable contraception using depot progestagens].
    Velasco Murillo V; Correu Azcona S
    Ginecol Obstet Mex; 1983 Jul; 51(315):191-7. PubMed ID: 6242048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statement on injectable contraception.
    International Planned Parenthood Federation IPPF
    IPPF Med Bull; 1982 Dec; 16(6):3-4. PubMed ID: 12338511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
    Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
    Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial.
    Hofmeyr GJ; Singata-Madliki M; Lawrie TA; Bergel E; Temmerman M
    Reprod Health; 2016 Apr; 13():42. PubMed ID: 27091008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bleeding patterns of adolescents using a combination contraceptive injection for 1 year.
    Bortolotti de Mello Jacobucci MS; Guazzelli CA; Barbieri M; Araújo FF; Moron AF
    Contraception; 2006 Jun; 73(6):594-7. PubMed ID: 16730490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status of injectable hormonal contraception, with special reference to the monthly method.
    De Aguilar MA; Altamirano L; Leon DA; De Fung RC; Grillo AE; Gonzalez JD; Canales JR; Sanchez Jdel C; Pozuelos JL; Ramirez L; Rigionni R; Salgado JS; Torres L; Vallecillos G; Zambrano EJ; Zea C
    Adv Contracept; 1997 Dec; 13(4):405-17. PubMed ID: 9404550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and acceptability of depo-medroxyprogesterone acetate injection. As a method of contraception in Saudi Arabia.
    Sobande AA; Al-Bar HM; Archibong EI; Sadek AA
    Saudi Med J; 2000 Apr; 21(4):348-51. PubMed ID: 11533816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New aspects of injectable contraception.
    Phillips OP
    Int J Fertil Womens Med; 2001; 46(1):31-6. PubMed ID: 11294618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Injectable contraception.
    Kaunitz AM
    Clin Obstet Gynecol; 1989 Jun; 32(2):356-68. PubMed ID: 2525977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depo-Provera use in an Australian metropolitan practice.
    Fraser IS; Dennerstein GJ
    Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.